Medicines based on the FluidCrystal technology have the potential to be administered by the patients themselves or by healthcare professionals, using an autoinjector pen with a non-visible needle or a pre-filled syringe, without time-consuming and complicated reconstitution procedures.

The long-acting release is designed with the intention to reduce the burden for the patient of frequent dosing. In combination with the possibility to self-administer, it can reduce the burden of the patient having to travel to an office visit to receive treatment. 

Mode of action

The FluidCrystal injection depot comprises a lipid-based liquid with a dissolved active ingredient that is injected subcutaneously. Upon contact with fluids in the tissue, the lipid solution transforms into a liquid crystalline gel, which encapsulates the active ingredient. The medicinal compound is slowly released as the liquid crystalline matrix gradually degrades in the tissue and the release can be controlled from several days to weeks or months depending on the composition.

By combining the FluidCrystal technology with well-established pharmaceutical substances with clinically documented efficacy and safety profiles, new proprietary medicines can be developed both in a shorter time, and to a lower cost compared to the development of medicines with new active substances.